Linked Life Data

11191886

Source:http://linkedlifedata.com/resource/pubmed/id/11191886

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2001-1-15
pubmed:abstractText
The use of sulphonamides is complicated by a high rate of cutaneous reactions in AIDS. Metabolic risk factors have been suspected for these reactions. We conducted a prospective study to evaluate whether glutathione S-transferase M1 null genotype, glutathione deficiency and acetylator status as risk factors. To explain the high frequency of slow acetylator phenotype in AIDS patients, we compared N-acetyltransferase-2 phenotype and genotype in this population. AIDS patients treated with sulphonamides for Pneumocystis carinii pneumonia or toxoplasmosis were followed up for cutaneous reactions. Glutathione S-transferase genotyping, glutathione level determination, N-acetyltransferase-2 genotyping and phenotyping were performed. One hundred and thirty-six AIDS patients were studied. Glutathione S-transferase M1 and T1 null genotypes, intracellular glutathione level, slow acetylator genotype and phenotype were not risk factors for cutaneous sulphonamides reactions. The association of glutathione S-transferase M1 null genotype and the slow acetylator one was a risk factor [Fisher's exact test, odds ratio (OR) = 2.6, 95% confidence interval (CI) = 1.2-5.9; P = 0.02]. A discordance between acetylator genotype and phenotype was found in 35% of patients. This frequency was significantly higher than the 6-7% expected (Fisher's exact test: OR = 7.5, 95% CI = 4.2-13.4; P < 0.0001). Suspected metabolic risk factors for sulphonamides cutaneous reactions were not confirmed prospectively. However, the association of glutathione S-transferase M1 null genotype and the slow acetylator one appeared to increase the risk of reactions. We clearly showed that the acetylation phenotype measured by caffeine probe could be modified by the disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0960-314X
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
821-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:11191886-Acetylation, pubmed-meshheading:11191886-Acquired Immunodeficiency Syndrome, pubmed-meshheading:11191886-Adult, pubmed-meshheading:11191886-Arylamine N-Acetyltransferase, pubmed-meshheading:11191886-Caffeine, pubmed-meshheading:11191886-Evaluation Studies as Topic, pubmed-meshheading:11191886-Female, pubmed-meshheading:11191886-Genotype, pubmed-meshheading:11191886-Glutathione Transferase, pubmed-meshheading:11191886-Humans, pubmed-meshheading:11191886-Male, pubmed-meshheading:11191886-Metabolic Detoxication, Drug, pubmed-meshheading:11191886-Middle Aged, pubmed-meshheading:11191886-Pneumonia, Pneumocystis, pubmed-meshheading:11191886-Prospective Studies, pubmed-meshheading:11191886-Risk Factors, pubmed-meshheading:11191886-Skin, pubmed-meshheading:11191886-Sulfonamides, pubmed-meshheading:11191886-Toxoplasmosis
pubmed:year
2000
pubmed:articleTitle
Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS.
pubmed:affiliation
Department of Dermatology, H pital Henri-Mondor, University Paris XII, Créteil, France. wolk@univ-paris12.fr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study